Idiopathic Multicentric Castleman's Disease

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Idiopathic Multicentric Castleman's Disease trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT07085039

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten bette…

United States14 participantsStarted 2025-12-18

Treatment: Ruxolitinib

All recent trials (2 shown)

Active — Not RecruitingPhase 2

NCT05345522

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

This study is a single-arm, open-label, multicenter, dose-escalation clinical study. Its primary purpose is to evaluate the safety and tolerability of recombina…

China25 participantsStarted 2022-04-18

Treatment: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w

Idiopathic Multicentric Castleman&#39;s Disease

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

All recent trials (2 shown)

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

All recent trials (2 shown)

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Idiopathic Multicentric Castleman's Disease